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Abstract   
Context: Findings have been perceived that only fewer children face 
COVID-19 and among infected, they have fewer violent signs. Being less 
severity among children could be significant for meditating therapeutics for 
high-risk adults and the elderly. 
 Evidence Acquisition: This study reviewed the main associated symptoms 
related to COVID-19 such as epidemiologic, laboratory-related, and 
therapeutic aspects among pediatric patients. In this narrative review, the 
most recent reproduced data on pediatric patients’ clinical revelation with 
COVID-19 have been considered and reviewed. 
Results: All ages of pediatric patients were susceptible against the COVID-
19. There wasn’t any significant sex difference. Asymptomatic, mild, or 
moderate signs were reported in more than 90% of all patients. Although 
pediatric patients clinical appearance of COVID-19 was commonly less 
severe compare to adult patients, young pediatric patients, exclusively 
infants, were vulnerable to infection. 
Conclusion: It is important that clinicians must be informed of possible 
clinical manifestations of pediatric patients ’COVID-19 cases to avoid 
neglecting or overdiagnosis of patients. As well as, this review provided 
strong documents of human-to-human transmission. 
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1. Context 
     Coronaviruses (CoVs), belonged to the 
family Coronaviridae, is a zoonotic single-
stranded RNA viruses. A variety of animals 
(including cattle, companion birds, and 
animals) can be infected by CoVs, with the 
potency to cause rigid cardiovascular, 
respiratory, enteric, and neurologic disease. 
[1-8] CoVs frequently cause symptoms of 
respiratory and gastrointestinal diseases, 
ranging from the common cold to syndrome 
related to severe acute respiratory distress 
(ARDS), coagulopathy, pneumonia, 
bronchitis, multi-organ failure, and even 
death in humans. Also, human 
coronaviruses (HCoVs) are related to some 
diseases such as asthma, cystic fibrosis, and
 
chronic obstructive pulmonary disease. [9-
11] 
In January 2020, in more than 170 
countries, COVID-19 has been widespread 
with rather than 500 000 cases. Only scant 
initial data on the burden of COVID-19 in 
pediatric patients was reported because the 
preliminary data focused on severe 
respiratory manifestations in adults.  Dong 
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et al, reported more than 2000 pediatric 
patients with COVID-19. Virologically, 
almost 4% had asymptomatic infection. 
Almost, this rate certainly understated 
asymptomatic infection true rate. Because 
many pediatric patients who were 
asymptomatic were unlikely to be tested. 
Otherwise, among pediatric patients who 
were symptomatic, only 5% had dyspnea or 
hypoxemia, and merely 0.6% proceeded to 
ARDS or multiorgan system dysfunction. In 
different studies has been reported that 
preschool-aged pediatric patients and 
infants were the same as older pediatric 
patients to have severe clinical 
manifestations (12-16). This review 
considered the main finding of COVID-19 
among pediatric patients according to 
epidemiologic, laboratory-related, and 
therapeutic aspects. 
 
2. Evidence Acquisition 
     In this narrative review, the most recent 
reproduced information on common sign 
and Covid-19 symptoms in pediatric 
patients and the idea that the coronavirus 
may have asymptomatic infection have been 
reviewed. Advancement in the 
understanding was so important because 
many pediatric patients who were 
asymptomatic were unlikely to be tested 
and neglected. Epidemiologically, this 
situation is so important because the 
importance of pediatric patients’ roles in 
transmitting of infections remains uncertain. 
 
3. Results 
The Main Epidemiologic Aspect of 
COVID 19 
     This review provided strong documents 
about human-to-human infections 
transmission related to Covid -19. Covid-19 
manifestations in pediatric patients were 
different ranging from a common cold, 
bronchitis, pneumonia, ADRS, multi-organ 
failure, and even death. Other members of 
coronaviruses family such as SARS-CoV, 
MERS-CoV and SARS-CoV-2 seemed to 
less effect on pediatric patients. Comparing 
to adults, they caused diseases with fewer 
symptoms, and lower case-fatality rates. 
Introductory, evidence proposed that 
pediatric patients were just the same as 
adults as of being infected with SARS-
CoV-2 .They were less presumably to be 
symptomatic or expand vigorous symptoms. 
Compared with adults, pediatric patients 
more frequently have gastrointestinal 
symptoms. In most pediatric patients with 
SARS-CoV, fever occurs, but the case for 
novel CoVs isn’t present. Many pediatric 
patients affected by MERS-CoV were 
without any symptoms. Most of the time, 
adults more often had a nosocomial 
exhibition; in contrast, the most of pediatric 
patients with novel CoVs have been proven 
indoor contact, frequently showing 
symptoms formerly them. This review 
summarizes epidemiologic, clinical, and 
diagnostic findings, with a focus on 
pediatric patients. [17] 
There are not many distributed archives 
including the clinical and chest CT 
discoveries of COVID-19 pneumonia in 
pediatric patients. As indicated by past 
examinations, there was a male-
overwhelmed propensity and scarcely any 
cases happened in pediatric patients for 
COVID-19 pneumonia. There was some 
clinical beginning manifestations qualities 
that were accounted for in pediatric patients 
including fever, cough, and fatigue, without 
other microbe contamination report 
(negative for Chlamydia pneumonia, 
respiratory syncytial virus, Mycoplasma 
pneumonia, Coxsackie virus B, Adenovirus, 
flu A, flu B, and human parainfluenza 
virus). The blood test was vague. Lab test 
demonstrated increased/ normal C-
responsive protein, decreased/normal blood 
leukocyte check, increased/normal 
lymphocyte count, reased/decreased/normal 
lymphocyte proportion, decreased/normal 
neutrophil proportion. CT documents were 
normal, single pure, single consolidation, 
multiple consolidations or ground-glass 
opacity (GGO). Different findings were 
with or without pleural emission and 
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without Lymphadenopathy. The pulmonary 
involvement in pediatric patient with 
COVID-19 was gentle with a central GGO 
or union. With COVID-19 epidemic and 
clinical features with or without lab 
affirmation, CT was the methodology of 
decision for early finding, seriousness 
appraisal, and convenient helpful impacts' 
assessment. For screening in pediatric 
patients versus chest CT, the introduction 
history and clinical indications were more 
useful. The CT documents in pediatric 
patients were different (from normal 
appearances to a few lesions injuries) 
including ground-glass haziness or lung 
consolidation. The introduction history and 
clinical side effects could be more useful for 
the screening, despite the fact that the 
pediatric patients' chest CT imaging 
highlights with COVID-19 pneumonia were 
vague. It was accounted for that HCoVs can 
be segregated from 4% to 6% of 
hospitalized pediatric patients with intense 
respiratory tract infections and from 8% of 
pediatric patients in a wandering setting. 
[18-21]  
The most regularly influenced of pediatric 
patients who have risk are younger than 3 
and pediatric patients with coronary illness. 
Most people seroconvert to HCoVs during 
adolescence, reinfections later in life are 
normal. There wasn’t any reduction in the 
relative of HCoVs infection prevalence with 
age increment, rather than other respiratory 
tract infections such as RSV respiratory 
syncytial virus. [22-27]  
Compared with pediatric patients coinfected 
with other respiratory viruses, pediatric 
patients with respiratory virus (HCoV) 
symptoms more likely suffered ongoing 
disease. [28] Normal flowing HCoVs in 
pediatric patients can cause regular cold 
manifestations, for example, fever, 
pharyngitis, rhinitis, laryngitis, otitis, and 
cerebral pain, yet additionally pneumonia, 
wheezing, bronchitis, bronchiolitis. 
Gastrointestinal manifestations are more 
normal in pediatric patients contrasted with 
grown-ups, with up to 57% of cases. In an 
investigation containing pediatric patients 
and adults’ sore throat, myalgia, fatigue, 
and headache were more normal in patients 
with HCoV compare to patients with RSV. 
Different indications were more regular in 
the last mentioned people (such as fever, 
cough and dyspnea). Few patients with 
HCoVs had fever compare to those patients 
contaminated with RSV or flu. [29-31]  
Human Covid NL63 was types of Covid 
that was distinguished in late 2004 of 
children with bronchiolitis in the 
Netherlands. In pediatric patients, HCoV-
NL63 has been related with febrile seizures, 
asthma intensifications, conjunctivitis and 
croup. Human Covid HKU1 (HCoV-
HKU1) is a types of Covid which started 
from infected mice. In people, infection 
brings about an upper respiratory malady 
with side effects of the regular cold, 
however can progress to pneumonia and 
bronchiolitis. It was first found in January 
2005 in two patients in Hong Kong. 
Resulting research uncovered it has 
worldwide dispersion and prior beginning. 
In pediatric patients, HCoV-HKU1 has been 
related with febrile seizures. The 
identification of HCoV in child CSF with 
intense dispersed encephalomyelitis or in 
adults CSF with numerous sclerosis was 
reported, yet uncommon instances of 
neurologic infections have likewise been 
proven .[32-34]  
Pediatric patients who were influenced by 
extreme intense respiratory condition 
related Covid (SARS-CoV) milder infection 
compare with adults, without deaths have 
been reported. In pediatric patients with 
SARS-CoV disease, some manifestation 
were accounted for as following : fever 
(91%–100%), cough (43%–80%),dyspnea 
(10%–14%), myalgia (10%–40%), sore 
throat (5%–30%), rhinitis (33%–60%), 
headache (14%–40%) and, less generally, 
vomiting (20%), diarrhea (10%) , 
abdominal pain (10%), and febrile seizures 
(10%). Absolutely, 30% of pediatric 
patients infected by SARS-CoV had a 
nosocomial contact and 50%–80% had 
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other relatives who were infected. More 
often, pediatric patients recuperate rapidly 
from a SARS-CoV infection. Some 
anomalies on CT eg. ground-glass 
pacifications with air trapping can endure 
for a while. [35-38]  
Middle East respiratory syndrome (MERS) 
is a viral respiratory malady brought about 
by a novel Covid (MERS‐ CoV), which 
was first distinguished in Saudi Arabia in 
2012. A low extent (0.1%–4%) of MERS-
CoV has been accounted for in pediatric 
patients. None of MERS-CoV tested 
positive was accounted for in a huge case 
arrangement of pediatric patients with 
intense respiratory tract disease who 
introduced to a tertiary emergency clinic in 
Saudi Arabia during the MERS-CoV 
scourge (2012–2013). Two different 
investigations were performed on pediatric 
patients infected with MERS-CoV, with a 
mean age of 7-10 years, 42% of pediatric 
patients were asymptomatic. In the other 
investigation of pediatric patients, 14% 
experienced cough and breath shortness, 
28% from diarrhea and vomiting, and 57% 
from fever. 28% of pediatric patients 
required oxygen supplementation and 14% 
mechanical ventilation. Household (32%) 
was the principle of MERS-CoV disease 
wellsprings in pediatric patients and 
different contacts (23%), trailed by 
nosocomial transmission (19%). Based on 
Chinese Centers for Disease Control and 
Prevention reports, pediatric patients were 
less regularly influenced by SARS-CoV-2, 
and just 2% were in people under 19 years 
old. Underlying disease was not reported 
the pediatric patients: 9% were 
asymptomatic, 65% had regular respiratory 
side effects, and 26% had mellow malady. 
The most well-known manifestations were 
cough (38%) and fever (50%). In any case, 
at times, fever introduction was with low to 
direct or even without any headache, fever, 
cough, rhinitis, fatigue, and diarrhea. In 
most cases poor feeding, dyspnea, and 
cyanosis was reported; however the 
numbers were not determined. Just 44% of 
infants were accounted for to have fever. 
Most infected pediatric patients with SARS-
CoV-2 recuperated two weeks after the 
beginning of indications and no death had 
been accounted for by February 2020. [39-
41]  
Some extraordinary and non-specific 
laboratory findings were accounted for from 
pediatric patients with novel CoVs during 
Covid illness of 2019 (Covid-19). The 
WBC was normal or diminished with 
diminished neutrophil as well as 
lymphocyte counts. CRP and procalcitonin 
levels were regularly typical. 
Thrombocytopenia maybe happened. It was 
reported that in serious cases, lactate 
dehydrogenase levels, liver enzymes, d-
dimers, and abnormal coagulation have 
been raised. [42-47] 
The most well-known blood findings of the 
COVID-19 were thrombocytopenia 
(32.8%), lymphopenia (75.9%), leukopenia 
(31.1%), with raised AST (aspartate 
aminotransferase) (24.6%), CK (creatinine 
kinase) (14.7%), lactate dehydrogenase 
(45.9%), ALT (alanine aminotransferase) 
(22.4%), and CRP (C-responsive protein). 
There is likewise a proposal that 
lymphopenia because of diminishes in T 
cells (both CD4+ and CD8+) may be a basic 
factor related with COVID-19 seriousness 
and fatality. [48-51] 
 
 Laboratory-related Aspect of COVID 19 
     All presumed cases are to be accounted 
for to region and state reconnaissance 
officials. Favored analytic test for SARS-
CoV-2 RNA is RT-PCR (reverse 
transcriptase polymerase chain reaction). 
For epidemiological purposes, next 
generation sequencing was used to 
recognize SARS-CoV-2 strains and 
transformations. Initial 7–10 days of 
disease, rapid serology kits which affirmed 
for clinical use, may not show positive 
results but for several weeks following 
contamination, results remain positive. 
Nasopharyngeal and oropharyngeal swab 
are favored samples for children not 
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accepting mechanical ventilation upper 
respiratory tract specimen; these ought to be 
transferred in VTM (viral transport media) 
on ice. In precisely for ventilated children, 
BAL (bronchoalveolar lavage) or 
endotracheal suction would be the favored 
specimen. These must be gathered into 
VTM and transported in the cold chain. 
Sputum specimen ought to be stayed away 
from in view of aerosol generation risk. In 
an indicative child, the viral load is relied 
upon to be high. Single test utilizing upper 
respiratory tract specimen such as 
nasopharyngeal and oropharyngeal swab 
ought to have the option to distinguish 
practically all the cases. All indicative 
children who have embraced global travel 
over the most recent 14 days or all 
hospitalized kids with serious intense 
respiratory sickness, for example, fever and 
cough as well as fatigue or asymptomatic 
direct . Between day 5 and day 14 after 
contacting, high-risks contacts of an 
affirmed case ought to be tested. [52-57] 
When viral RNA degree being underneath 
the constraint of test identification, COVID-
19 false negatives results happen .Best 
example types are assortment techniques 
and testing stages include on SARS2-CoV 
detection. It could help clarify why SARS-
CoV-2 tests were negative when the patient 
has clinical symptoms. Microbiology 
dogma directs that good specimen 
assortment prompts exact outcomes from 
the lab. Nasopharyngeal swabs are the 
favored specimen type for COVID-19 
according to CDC.CDC permit taking 
oropharyngeal swab for gathering samples. 
It is controversial on saliva using to 
diagnose COVID-19 disease. Generally, it 
was proven that a patient who is 
contaminated with SARS-CoV-2 high viral 
load may have contradictory results. LOD 
means the limit of detection.LOD of a RT-
PCR test describes the RNA base 
measurement that will distinguish 95 out of 
100 times. About patients contaminated 
with SARS-CoV-2 without test positive, a 
high false- negative outcome will prompt. If 
the LOD for a test is excessively low, it 
means the test will recognize viral RNA 
smallest measurement, prompting false-
positive test outcomes. Individuals with 
SARS-CoV-2 will be positive rather than 
negative. Clinically, RNA specialty 
identified in an individual is critical. The 
target LOD for a precise test is simply that 
craftsmanship. [58] 
So, for NAT; blood and stool samples 
collecting at disease later periods increase 
the positive results whether being the 
inaccessible of lower respiratory tract 
specimens. Volume expanding raise 
identification affectability. Placing samples 
in guanidine salt reagents inactivate virus 
and protect RNA.In addition, setting 
appropriate positive, and negative controls 
to gain great outcomes; at the same time 
enhancing human RNase P quality to avoid 
false-negative results. For immune response 
assay, assorted measures focusing on 
various antigens, and gathering paired 
samples are needed. [59] 
 
Therapeutic Aspects of COVID 19 
     For the flu, on potential bacterial-SARS-
CoV-2 co-infection treatment was focused. 
This suggestion has been applied in 
COVID-19 treatment which accounted for 
SARS-CoV-2 infection in China. Being 
insufficient data, NIH recommend for 
empiric broad-spectrum antibiotic therapy 
in the absence of another indication in 
severe or critical illness, and patients with 
COVID-19. In the guidelines of Infectious 
Diseases Society of America this issue has 
been ignored. Conversely, the Surviving 
Sepsis Campaign specialists utilize empiric 
antimicrobials/antibacterial therapy in 
ventilated patients with COVID-19 and 
respiratory distress. in spite of the fact that 
they are with a low degree of proof-
dependent on the information extrapolated 
from past examinations on different sorts of 
viral types of pneumonia, especially flu. 
Empiric antimicrobials therapy in Taiwan 
and Canada for treating all presumable 
bacteria causing respiratory disease and 
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sepsis. The decision ought to be founded on 
the clinical conclusion, susceptibility tests, 
and local epidemiology. In UK, antibiotics 
should just be offered to patients with 
suspected or affirmed COVID-19, if the 
probable reason is bacterial agent. When the 
patients are at high risks group whether the 
agent is bacteria or virus it stays hazy. 
Especially, oral doxycycline is favored 
against M. pneumonia and S. aureus. In 
China country, for COVID-19 patients with 
suspected co-bacterial infection 
azithromycin, amoxicillin, and 
fluoroquinolones was suggested for mild 
cases however wide range anti-infection 
covering all potential microbes was 
recommended for serious cases. In light of 
the restricted information of the current 
work, it stays indistinct which antimicrobial 
operators ought to be experimentally 
recommended in patients with suspected 
COVID-19. To prevent antimicrobial 
resistance rising due to = inappropriate 
antibiotic utilization for viral pneumonia, 
antimicrobial susceptibility testing should 
be done. [60-69] 
 
4. Conclusion 
     Within the sight of COVID-19, 
clinicians must know about the conceivable 
clinical indications of pediatric patients' 
COVID-19 cases to abstain from neglecting 
or overdiagnosis of patients. 
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